IDXGOTCSurgical & Medical Instruments & ApparatusFiscal year ends December 31
INTERPACE BIOSCIENCES, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$5.00−0.15 (-2.91%)
Close on Oct 19, 2026
- Market cap
- $138.57M
- P/E (TTM)
- 5.6
- Dividend yield
- –
INTERPACE BIOSCIENCES, INC. revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2014 | FY2013 | FY2012 | FY2011 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|
| Reportable Segment [Member] | $38.73M | $46.93M | $40.04M | – | – | – | – | 100.0% | -17.5% |
| Commercial Services [Member] | – | – | – | $118.46M | $146.53M | – | – | – | – |
| Diagnostic Services [Member] | – | – | – | $1.47M | $0 | – | – | – | – |
| Operating income | FY2025 | FY2024 | FY2023 | FY2014 | FY2013 | FY2012 | FY2011 | YoY |
|---|---|---|---|---|---|---|---|---|
| Marketing Services [Member] | – | – | – | – | -$4.39M | -$27.47M | -$9.49M | – |
| Product Commercialization Services [Member] | – | – | – | – | $1.87M | $3.16M | $1.52M | – |
| Sales Services [Member] | – | – | – | – | -$1.75M | -$930.00K | $3.27M | – |
| Commercial Services [Member] | – | – | – | -$3.17M | -$980.00K | – | – | – |
| Diagnostic Services [Member] | – | – | – | -$10.30M | -$457.00K | – | – | – |
By product or service
By region
From the segment and revenue-disaggregation notes of Interpace Biosciences's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.